Stock Events

Stock Events

Macrogenics 

$4.17
53
-$0.00-0.12% 15:55 Today

Statistics

Day High
4.19
Day Low
4.05
52W High
5.08
52W Low
1.29
Volume
139,094
Avg. Volume
906,545
Mkt Cap
265.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.73
-0.38
-0.04
0.31
Expected EPS
-0.2902
Actual EPS
N/A

Financials

-49.91%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
149.5MRevenue
-74.62MNet Income

Analyst Ratings

8.50Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MGNX. It's not an investment recommendation.
Microsoft
12
MSFT
Amazon
11
AMZN
NVIDIA
11
NVDA
Apple
9
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation works on small molecule drugs for cancer, which competes with Macrogenics' approach to cancer treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals focuses on monoclonal antibodies for cancer and other diseases, competing with Macrogenics' antibody-based therapies.
AMGEN
AMGN
Mkt Cap224.63B
Amgen develops biologic treatments for various conditions, including cancer, competing with Macrogenics in the biopharmaceutical space.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, known for antiviral drugs, has expanded into oncology, competing with Macrogenics in the cancer treatment market.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb, with a broad portfolio including cancer therapies, competes with Macrogenics in developing treatments for cancer.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a diverse range of cancer treatments, competing with Macrogenics in the oncology market.
Novartis
NVS
Mkt Cap286.78B
Novartis focuses on innovative healthcare solutions, including cancer treatments, competing with Macrogenics in the field of targeted therapy.

About

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Show more...
CEO
Eric Risser
Employees
293
Country
United States
ISIN
US5560991094
WKN
000A1W6ND

Listings

STU
DE
M55.STU
BOATS
BOATS
MGNX.BOATS
XNAS
US
MGNX
F
DE
M55.F

0 Comments

Share your thoughts

FAQ

What is Macrogenics stock price today?▼
The current price of MGNX is $4.17 USD — it has decreased by -0.12% in the past 24 hours. Watch Macrogenics stock price performance more closely on the chart.
What is Macrogenics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Macrogenics stocks are traded under the ticker MGNX.
Is Macrogenics stock price growing?▼
MGNX stock has risen by +2.45% compared to the previous week, the month change is a -3.24% fall, over the last year Macrogenics has showed a +180.54% increase.
What is Macrogenics market cap?▼
Today Macrogenics has the market capitalization of 265.31M
When is the next Macrogenics earnings date?▼
Macrogenics is going to release the next earnings report on November 04, 2026.
What were Macrogenics earnings last quarter?▼
MGNX earnings for the last quarter are 0.31 USD per share, whereas the estimation was -0.08 USD resulting in a +498.17% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Macrogenics revenue for the last year?▼
Macrogenics revenue for the last year amounts to 149.5M USD.
What is Macrogenics net income for the last year?▼
MGNX net income for the last year is -74.62M USD.
How many employees does Macrogenics have?▼
As of August 20, 2026, the company has 293 employees.
In which sector is Macrogenics located?▼
Macrogenics operates in the Health & Wellness sector.
When did Macrogenics complete a stock split?▼
Macrogenics has not had any recent stock splits.
Where is Macrogenics headquartered?▼
Macrogenics is headquartered in Rockville, United States.